Sarecycline Seysara denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sarecycline seysara are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sarecycline (Seysara) as Experimental

Blue Cross Blue Shield occasionally issues an "experimental or investigational" denial for sarecycline, typically because a reviewer applied an outdated policy or failed to confirm the drug's FDA-approval status. Sarecycline holds a current FDA approval specifically for the treatment of moderate-to-severe acne vulgaris in adults and adolescents. An experimental denial on an FDA-approved medication is a recognized administrative error that has a strong track record of reversal on appeal.

### Why This Denial Is Appealable

Federal and state insurance law defines "experimental" as a treatment lacking adequate evidence of safety and efficacy or lacking relevant regulatory approval. An FDA-approved drug used within its approved indication does not meet that definition. BCBS's own coverage policies ordinarily exclude FDA-approved drugs from experimental classification when used on-label. Documenting the FDA approval and the on-label nature of the prescribed use is often sufficient to overturn this type of denial.

### Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plans) or ACA §2719 (individual/small-group plans). Deadlines are printed on your denial notice — act promptly.
• External review: ACA §2719 guarantees access to an independent external review organization after an adverse internal decision. You typically have roughly four months from the final internal denial to request external review, but confirm the precise date on your Explanation of Benefits.
• Expedited review: Available when a standard timeline would seriously jeopardize your health. Request it explicitly in writing.

### Concrete Appeal Steps

1. Obtain the FDA approval letter or the FDA product label for sarecycline (publicly available on the FDA website) confirming the approved indication. 2. Identify the exact language in BCBS's coverage policy that defines "experimental" and confirm sarecycline does not meet it. 3. Have your prescriber write a medical-necessity letter confirming the on-label use and referencing the FDA-approved indication. 4. Submit the internal appeal citing the FDA approval directly and requesting that BCBS specify which element of its experimental-criteria definition the drug fails. 5. If denied internally, escalate immediately to external review.

### Documentation to Gather

• FDA approval confirmation: Printout or citation of the FDA-approved prescribing information (label) confirming indication and approval date.
• On-label use confirmation: Chart note or prescriber letter stating the prescribed use matches the FDA-approved indication.
• Diagnosis documentation: Dermatology chart notes confirming moderate-to-severe acne vulgaris.
• BCBS policy language: A copy of the relevant experimental/investigational coverage policy to cross-reference.
• Criteria mapping: List each element of BCBS's experimental definition; document factually that sarecycline satisfies none of them.

### Key Reminder

Always retrieve the current version of BCBS's experimental/investigational coverage policy directly from their website or by calling the member services number on your insurance card — policy language can change and the version that applies to your claim date is the controlling document.